Munc18-2 is required for Syntaxin 11 Localization on the Plasma Membrane in Cytotoxic T-Lymphocytes

Nele M.G. Dieckmann1, Yvonne Hackmann1,2, Maurizio Aricò3 and Gillian M. Griffiths1*

1Cambridge Institute for Medical Research, Cambridge Biomedical Campus, University of Cambridge, Cambridge CB2 0XY, United Kingdom
2Current address: Biochemistry Center, Heidelberg University, Heidelberg, Germany
3Azienda Sanitaria Provinciale 7, Piazza Igea 1, I-97100 Ragusa, Italy
*Corresponding author, Gillian M. Griffiths, gg305@cam.ac.uk

Abstract

Cytotoxic T-lymphocytes (CTL) kill their targets by cytolkytic granule secretion at the immunological synapse. The Sec/Munc protein, Munc18-2, and its binding partner Syntaxin 11 (STX11) are both required for granule secretion, with mutations in either leading to the primary immunodeficiency, Familial Haemophagocytic Lymphohistiocytosis (FHL4 and 5). Understanding how Munc18-2 and STX11 function in CTL has been hampered by not knowing the endogenous localization of these proteins. Using a novel FHL5 Munc18-2 mutation that results in loss of protein, cytotoxicity and degranulation together with CTL from an FHL4 patient lacking STX11, enabled us to localize endogenous STX11 and Munc18-2 in CTL. Munc18-2 localized predominantly to cytolkytic granules with low levels associated with the plasma membrane where STX11 localized. Importantly, while Munc18-2 localization is unaffected by the absence of STX11 in FHL4 CTL, STX11 is lost from the plasma membrane in FHL5 CTL lacking Munc18-2. These findings support a role for Munc18-2 in chaperoning STX11 to the plasma membrane where the final fusion events involved in secretion occur.

Keywords: CTL, FHL4, FHL5, Munc18-2, Syntaxin 11

CD8-positive cytotoxic T-lymphocytes (CTL) are key players of the mammalian immune system, providing protection from viral infection and cancerous cells. CTL kill through precise delivery of perforin and granzymes across a highly organized CTL:target interface that is known as the immune synapse. CTL protect themselves from the potent pro-apoptotic factors by storing these proteins in specialized secretory lysosomes, termed cytolkytic granules. During CTL attack, these granules are delivered to the synapse where they fuse with the plasma membrane and release their deadly contents onto the target (reviewed in 1).

The biogenesis of cytolkytic granules and their final fusion with the plasma membrane requires a specialized fusion machinery. Two components of this are the SNAP (Soluble NSF Attachment Protein) Receptor (SNARE)-protein Syntaxin 11 (STX11) (2) and the Syntaxin binding protein Munc18-2 (3,4) and genetic mutations that cause loss of function of either of these proteins gives rise to Familial Haemophagocytic Lymphohistiocytosis (FHL), a devastating autosomal hereditary immune deficiency condition that is marked by the failure of CTL to kill infected cells efficiently (reviewed by 5,6).

In neuronal and epithelial cells, Munc18 proteins were found to be required for stable plasma membrane localization of Syntaxin 1A (STX1A) (7,8). Interestingly, in FHL5 patient CTL (in which Munc18-2 is lost) STX11 levels...
are usually strongly reduced and the inability of STX11 and Munc18-2 deficient cells to kill target cells efficiently was shown to be due to a degranulation defect (3,4,9). This led to the suggestion that a chaperoning interaction similar to the Munc18/STX1A pair is given between Munc18-2 and STX11 and that the two proteins drive the last step of granule secretion at the CTL plasma membrane (3,4,9–12). Notably, the finding that FHL5 patients with mutations R65Q/W retain the ability to interact with STX11 supports an additional direct role in secretion for Munc18-2 (13). Whether Munc18-2 and STX11 function at the plasma membrane, or at a late granule maturation step (14) remains unclear, in part due to the lack of information on the precise localization of these proteins.

STX11 and Munc18-2 are widely expressed (15–17) and studies in other secretory cells flagged up several roles for Munc18-2 on compartments other than the plasma membrane. In mast cells, Munc18-2 on the limiting membrane of secretory granules appeared to provide a link to microtubules and thus promote the transport of granules to the cell periphery (18). A study in the pancreatic beta-cell line MIN6 reported a role for Munc18-2 in modulating calcium responsiveness during the secretion of granules. Sucrose gradient analysis detected Munc18-2 predominantly in low-density fractions that correspond to ‘small membranous organelles and soluble proteins’ (19). Furthermore, it has been suggested that in CTL the granules themselves undergo one (or several) maturation steps before they become ‘secretion competent bullets’ that carry all the machinery required for fusion at the plasma membrane (14). These reports highlight multiple potential roles for Munc18-2 but exactly when and where STX11 and Munc18-2 function in CTL is not fully understood.

Precise localization of proteins within the cellular environment can give important clues about their function. However, several issues have been reported previously when it comes to the localization of tagged SNARE-protein and Munc18-2 constructs: One of the key functional domains of any SNARE-protein is either a transmembrane domain or a lipidic membrane anchor enabling these proteins to associate directly with membranes (review: 20,21). Thus, when a SNARE is even slightly over-expressed, the possibility of mis-localization of the tagged construct to non-physiological compartments is a major concern. Although it has been reported that over-expressed STX11 localizes to the recycling endosome in human CTL it is not known whether this corresponds to localization of the endogenous protein (12,22). Munc18-2 on the other hand has no domains that suggest an ability to associate with membranes independently of helper proteins. Indeed over-expressed Munc18-2 constructs remain diffuse cytoplasmic (23) unless a membrane-associated binding partner such as STX11 is expressed in parallel (24).

We therefore assessed the distribution of endogenous Munc18-2 and STX11 in CTL. Four new polyclonal antibodies were raised against near full-length human Munc18-2 and STX11 protein. By comparing immunofluorescence microscopy (IF) in healthy donor (HD) CTL versus FHL4 and FHL5 patient cells, lacking Munc18-2 or STX11, we were able to determine specific staining and now show the localization of endogenous Munc18-2 and STX11 in human CTL. In order to do this we also report a novel patient mutation in Munc18-2 that abolishes protein expression, and used CTL from a previously reported patient mutation lacking STX11. This approach allowed us to define the endogenous localization of both proteins. Our data reveal that endogenous Munc18-2 localizes predominantly to the cytolytic granules, with low levels on the plasma membrane, and is required for STX11 delivery to the plasma membrane.

**Results**

**FHL4 and FHL5 CTL validate STX11 and Munc18-2 antibody specificity**

FHL4 CTL with a homozygous loss of the entire STX11 coding exon (AL135917:g.25561-44749_del, 25) and FHL5 CTL with a homozygous deletion-insertion mutation (c.1468_1470delCGGinsTGGACAGCCCTGGAGGG p.R490WfsX95, UPN666), leading to a frameshift from amino acid 490 onwards and predicting a premature stop-codon were used to confirm the antibody specificities (Figure 1A).

Western blotting with the Munc18-2 and STX11 antibodies 5182 and 5412 showed a complete loss of Munc18-2 and STX11 protein from the FHL4 and 5 CTL, respectively. As described previously for other FHL5 patients (3,4) STX11 levels are reduced in the absence of Munc18-2 (Figure 1B).
Figure 1: FHL4 and FHL5 patient CTL establish Syntaxin 11 and Munc18-2 antibody specificity. A) Schematic representation of the STX11 and Munc18-2 amino acid sequences indicating the effects of the homozygous mutations present in the FHL4 (847–1850) and FHL5 (UPN666) patient cells used in this study compared to healthy donor (HD). B) Western Blots on human CTL lysates against Munc18-2 and STX11 using the two polyclonal rabbit antibodies 5182 and 5412. C) Percentage of P815 target cells lysis (% killing) for HD (solid black line, squares) or FHL5 patient UPN666 CTL (dotted black line, triangles) at Effector:Target ratios shown. CTL, 10 days post restimulation. D) Granule release assay showing surface LAMP1 after 30 minutes PMA-Ionomycin stimulation of CTL from HD (solid black) and FHL5 patient UPN666 (dotted black line). Solid gray line: unstimulated HD CTL. CTL, 10 days post restimulation.

The frameshift mutation in UPN666 has not been described before. We therefore investigated the effects of this novel mutation on CTL killing and degranulation and found both to be reduced even after 2 weeks of culture in the presence of IL-2 (Figure 1C,D). This stands in contrast to several previously published FHL5 patient CTL that did not show abnormal cytotoxicity in culture (26).

Endogenous Munc18-2 localizes to cytolytic granules and the plasma membrane in human CTL

We tested both anti-Munc18-2 antibodies (5182 and 5184) by IF on HD as well as FHL5 CTL (Figure 2). In HD derived CTL, both antibodies localized predominantly to intracellular granules and a central puncta, with low levels detected on the plasma membrane. We subsequently focused on antibody 5182 because it provided a stronger signal. By staining HD and FHL5 patient cells in parallel we confirmed that the granular and the plasma membrane staining are specific to Munc18-2 (Figure 2A,B). Colocalization with LAMP1 (n = 158 HD cells) and the cytolytic granule marker perforin (n = 119 HD cells) identified the predominant granular staining as the cytolytic granules. Munc18-2 colocalized with LAMP1 on the limiting membrane of the granule (Figure 2C) surrounding perforin (Figure 2D). This staining was lost from FHL5 CTL (Figure 2A–D) while the central puncta, identified as the centrosome by gamma-tubulin colocalization, remained (data not shown). A weak cytoplasmic staining could also be detected in HD cells, consistent with a small pool of Munc18-2 dispersed throughout the cytoplasm. With six independent experiments revealing strong granular staining in HD CTL, our experiments suggest that endogenous Munc18-2 is localized to cytolytic granules in CTL. Although some plasma membrane staining was observed it was weaker and variable between experiments (Figure 2A–D). When Munc18-2 was observed on the
Figure 2: Legend on Next page.
plasma membrane an accumulation was seen at the leading edge in 30% of cells (Figure 2A,B).

As Munc18-2 localized to cytolytic granules in CTL, we asked whether this was maintained when granules polarized toward target cells. Two-thirds of CTL-target conjugates showed granules clustered at the immunological synapse, and in each case Munc18-2 remained associated with the granules (Figure 2E, \( n = 63 \)). Any plasma membrane staining remained equally distributed in all conjugates without accumulation at the synapse (Figure 2E).

**Endogenous STX11 associates with the plasma membrane accumulating at the leading edge of human CTL**

We next sought to determine whether STX11 localized to the same cellular compartments as Munc18-2. Again, both our custom-made STX11 antibodies (5412 and 5413) showed the same staining pattern in CTL and one antibody (5412) yielded considerably stronger signal.

In five independent experiments we compared STX11 staining with 5412 in HD cells (\( n = 328 \)) and FHL4 control cells (\( n = 312 \)). We observed staining of the plasma membrane exclusively in HD cells while punctate cytoplasmic and centrosome staining was found in both HD and FHL4 cells, suggesting that these signals were non-specific (Figure 3A). It should be noted that as cells were fixed with methanol any free cytoplasmic pool of STX11 would be lost after fixation. Hundred percent of HD CTL showed plasma membrane localization of STX11, with 30% showing accumulation at the leading edge (Figure 3B). In CTL-target conjugates, STX11 accumulated either across or clustered at the immune synapse in \( \leq 16\% \) of conjugates (Figure 3C). In contrast to Munc18-2 we did not observe colocalization of STX11 with LAMP1 (Figure 3D).

**Munc18-2 localization is independent of STX11 but in the absence of Munc18-2, STX11 is lost from the plasma membrane**

It has been suggested that Munc18-2 might act as a chaperone to transport STX11 to the plasma membrane as observed for the Munc18/STX1A pair (7,8). Therefore, we asked whether the localization of endogenous STX11 at the plasma membrane depends upon the presence of Munc18-2 and vice versa. We performed parallel Munc18-2 and STX11 staining in HD, FHL4 and FHL5 cells in three independent experiments and co-stained with LAMP1 or CD8 in order to assess potential effects on colocalization with these markers.

As observed previously, we found strong Munc18-2 staining on granules and weaker staining on the plasma membrane in HD cells (\( n = 265 \)) but no Munc18-2 staining on FHL5 cells (\( n = 263 \)). Centrosomal staining was non-specific as it was present in both HD and patient cells. Munc18-2 staining in FHL4 cells (\( n = 252 \)) resembled staining in HD cells, indicating that Munc18-2 localization was not affected by the absence of STX11. In contrast, FHL5 CTL (lacking Munc18-2) completely lost the plasma membrane STX11 localization seen in HD CTL (Figure 4), confirmed by colocalization with the T cell plasma membrane protein, CD8 (Figure 5). These results support a role for Munc18-2 in STX11 stability and are consistent with...
Localization of Endogenous STX11 & Munc18-2 in CTL

Figure 3: Endogenous STX11 is on the plasma membrane of human CTL. A) Localization of STX11 in healthy donor (HD) and FHL4 patient 847–1850 CTL using antibody 5412. White arrowheads: leading edge. B) Percentage of cells with plasma membrane staining for HD (white, n = 328) and FHL4 (black, n = 312) CTL using antibody 5412. PM: plasma membrane staining, hatched bar = HD CTL with an accumulation of STX11 at the leading edge. Results shown as mean from five independent experiments with standard deviation, *** indicate a significant difference with p << 0.0001, two-tailed students t-test (unpaired), 95% confidence limits. C) STX11 staining using antibody 5412 in HD CTL-target conjugates illustrating STX11 accumulation at the synapse (5 experiments, n = 128). D) Co-staining for anti-STX11 5412 (green) and LAMP1 (red) in HD cells (2 experiments, n = 135). Yellow lines (i) and (ii) were drawn via the IMAGEJ line tool (linewidth: 3 pixel) to obtain STX11 and LAMP1 intensity profiles. All images show single confocal planes. Scale bars: 5 μm.

a role for Munc18-2 in chaperoning STX11 to the plasma membrane.

Discussion

Munc18-2 and STX11 play essential roles in secretion from CTL and NK cells. Mutations in the genes encoding these two proteins give rise to FHL, a profound immunodeficiency that can be cured only by bone marrow transplantation. Functional studies have shown that these proteins play a role in secretion (2 – 4), but do not reveal at which stage in the secretory pathway they are required. In order to identify the sites of action of Munc18-2 and STX11 we asked where the endogenous proteins were localized in CTL.

There are two well-acknowledged problems with establishing the cellular localization of SNARE and associated Munc18 proteins: over-expression often results in mis-localization because SNARE component proteins can recombine promiscuously and levels of binding partners become limiting (7,20,27). Furthermore, the multitude of homologous proteins (15 syntaxins; 3 Munc18-proteins) means that it can be difficult to determine the specificity of antibody binding for any single protein. In order to overcome these difficulties, we investigated the localization of endogenous STX11 and Munc18-2 in human CTL through the use of novel antibodies raised against (near) full-length human Munc18-2 and STX11 protein. Importantly, the use of patient CTL lacking STX11 (FHL4) and Munc18-2 (FHL5) allowed us to establish the specificity of staining. Our results demonstrate that endogenous Munc18-2 is localized predominantly on secretory lysosomes of CTL although lower levels are observed on the plasma membrane, where STX11 is found, raising the possibility that
Dieckmann et al.

Figure 4: Munc18-2 localization is independent of STX11 but in the absence of Munc18-2, STX11 is lost from the plasma membrane. Localization of endogenous Munc18-2 and STX11 in CTL from healthy donor (HD) ($n = 265$), FHL4 (847–1850, $n = 252$) and FHL5 (UPN666, $n = 263$) using antibodies 5182 and 5412 respectively. All images show single confocal planes and represent three independent experiments. Scale bars: 5 μm.

Munc18-2 might transit the plasma membrane and deliver STX11 to this site.

Previous studies in CTL and NK cells have examined the localization of over-expressed, tagged constructs of these proteins (11,12,22,24,28) or using antibodies raised against peptide or mouse epitopes in human CTL (13,29). These studies suggested many possible localizations in CTL, with Munc18-2 diffusely cytoplasmic (24), on dense puncta (13) or associated with cytolytic granules (24) and STX11 on distinct cytoplasmic puncta (11,12,22,28,29) colocalizing with CD3 and granzyme B (12) but not perforin (28,29) and/or associated with the plasma membrane (12,24).

Our localization of endogenous STX11 staining confirms the plasma membrane component of the localization observed when TFP-STX11 and GFP-STX11 was expressed in human CTL and YTS NK cells, respectively (12,24). However, we do not observe the additional localization of STX11 on vesicular structures observed when
Figure 5: STX11 colocalizes with CD8 at the plasma membrane. Co-staining for anti-STX11 5412 (green) and plasma membrane marker CD8 (red) in healthy donor (HD) (n = 149, 4 experiments), FHL4 (847–1850, n = 144, 4 experiments) and FHL5 (UPN666, n = 56, 1 experiment) CTL. Yellow lines (i) and (ii) were drawn via the IMAGEJ line tool (linewidth: 15 pixel) to obtain STX11 and CD8 intensity profiles. All images show single confocal planes. Scale bars: 5 μm.
STX11 is over-expressed (12,22,24,28) or with previous antibody localizations (13,29). Although vesicular staining was observed in several studies, there was little consensus over the identity of this compartment. Recent reports based on over-expressed TFP-STX11 colocalization with mCherry-Rab11a propose a model by which STX11 is only delivered to the plasma membrane immediately prior to granule fusion via VAMP8-mediated fusion of the recycling endosome (12,22). In the present study, we show that there is a steady-state localization of endogenous STX11 on the plasma membrane, which requires Munc18-2 for its delivery to this site.

Interestingly in a previous study the diffuse cytoplasmic GFP-Munc18-2 localization changed to a vesicular colocalization with mcherry-Munc18-2 when both Munc18-2 and STX11 were over-expressed, demonstrating the inter-dependence of these two proteins and the importance of determining the endogenous localization of these proteins with physiological expression levels (24).

The localization of Munc18-2 on cytolytic granules in CTL that we observe matches the endogenous Munc18-2 staining observed on the secretory granules of mast cells (18,30) and in neutrophils (31). Intriguingly these granules are all secretory lysosomes, suggesting that Munc18-2 localizes to this compartment in immune cells.

We found the distribution of Munc18-2 to be the same in HD cells and STX11-deficient FHL4-cells. This suggests that Munc18-2 does not depend on STX11 for its association with granule membranes and the plasma membrane and could be explained by Munc18-2 associating with an alternative SNARE-protein in the absence of STX11. Hackmann et al. (25) demonstrated that the N-terminal peptide of the STX11 homologue Syntaxin3 (STX3) binds Munc18-2 in vitro (albeit with 20 times lower affinity compared to the STX11 peptide) and that STX3 expression is upregulated through IL-2 culture of human NK cells, a culture condition that has previously been reported to partially restore granule release and killing through FHL4 and five NK cells and CTL (2–4,32). Hackmann et al. furthermore showed STX3 re-localized from intracellular vesicles to the plasma membrane in STX11 deficient CTL. These findings suggest STX3 as one likely candidate for interaction with Munc18-2 at the granule and plasma membrane in the absence of STX11. Conversely, STX11 is lost from the plasma membrane in FHL5 patient cells lacking Munc18-2. STX11 thus appears to require Munc18-2 either to reach the plasma membrane or to remain stably associated with it, although we cannot rule out the possibility that Munc18-2 might stabilize STX11 at an earlier stage during its biosynthesis. Either way, Munc18-2 appears to be required to build up a steady-state pool of STX11 on the plasma membrane of CTL.

Two observations invite further speculation on additional roles for both proteins: STX11 readily accumulates at the leading edge of migrating CTL but we only rarely observed an accumulation at the immune synapse. Fusion of the small number of cytolytic granules that is needed to eliminate a target may not necessarily require a high density of SNARE proteins. At the leading edge of a migrating cell, however, a high number of vesicles that deliver migratory or target sensing factors to the plasma membrane may need to be turned over (33) and it is tempting to speculate that STX11 may be involved in these processes. Similarly, based on the fact that only Munc18-2 (but not STX11) localized to CTL granules it is possible that Munc18-2 may play additional roles on this compartment as previously suggested for granular Munc18-2 in mast cells (18).

Materials and Methods

Cells

Patient UPN666 presented at the age of 1 month with full-blown HLH (fever, splenomegaly, bi-cytopenia, low plasma levels of fibrinogen, high levels of triglycerides and ferritin). Functional study showed defective GRA results; sequencing of the Syntaxin binding protein 2 (Munc18-2) (STXBP2) gene revealed a homozygous deletion-insertion mutation (c.1468_1470delCGGinsTGGACAGCCCTGGACAGGG p.R490WfsX95), leading to a frameshift at amino acid 490 and predicting a premature stop-codon 95 amino acids later; thus, FHL5 was diagnosed. Ethical approval was obtained in accordance with the standards of the Declaration of Helsinki. A bulk CD8 line (CTL) FHL4 patient (847–1850) was described previously (25). Bulk CD8+ cells from the FHL5 patient (UPN666) were isolated by negative selection from peripheral blood mononuclear cells (PBMCs) using the Dynabeads Untouched Human CD8 T-cell purification kit from Invitrogen. HD CTL were from donor 434–722.

Cell culture

CTL were cultured at 37°C in a humidified atmosphere with 8–10% CO2 in RPMI 1640, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.9 mM sodium
bicarbonate, 50 μM beta-mercaptoethanol (Invitrogen-GIBCO), 5% human AB-Serum (SeraLab) and recombinant human IL-2 (100 U/mL). CTL were stimulated every 3–4 weeks using irradiated PBMCs isolated from buffy coats in the presence of PHA. Whole human blood was collected from HDs with informed consent from individuals and pre-

followed by an additional wash in PBS-Tween solution and incubated with HRP-coupled secondary antibody in blocking buffer for 30–45 min at room temperature. Membranes were washed as before followed by an additional wash in PBS for 10 min. Blots were developed using ECL Western Blotting solutions (Amersham).
well and stored on ice in the dark until all time points were collected. Cells were pelleted, resuspended in FACS buffer plus anti-CD8-APC antibody (50 μL per well) and incubated for 30 min on ice in the dark. Cells were washed 1x and resuspended in 160 μL FACS buffer per well. Cells were analyzed using a FACSCalibur instrument (Becton Dickson) and FlowJo software where gates were set as follows: Live cells (based on forward versus side scatter), CD8+ T-cells (based on APC staining), CD8+/LAMP1+ T-cells based on PE-staining. The use of PE and APC fluorophores meant that no compensation was necessary during data acquisition. % of Max is ‘the number of cells in each bin divided by the number of cells in the bin that contains the largest number of cells’. Bins are defined as ‘numerical ranges for the parameter on the X axis’ (FlowJo manual, http://www.flowjo.com/v6/html/faq.html#2.4.4).

Acknowledgments

This work was funded by grants from the Wellcome Trust [075880, 100140] (G.M.G) and [097024] (N.D.); a Daimler Benz scholarship (Y.H.); the Kendal-Dixon Fund (Y.H.); the Cambridge European Trust (Y.H.); King’s College (Cambridge) (Y.H.); the National Institute for Health Research Biomedical Research Center (G. M. G); Antonio Pinzino – Associazione per la Ricerca sulle Sindromi Emofagocitiche (M.A.); Associazione Italiana Ricerca Istitiocitosi (M.A.); and Italian Ministry of Health, Progetto dioce ricerca finalizzata 2008, Bando Malattie Rare RF-TOS-2008-1219488 (M.A.). We would like to thank the CIMR flow cytometry core facility. The authors report no conflict of interests.

References

1. Angus KL, Griffiths GM. Cell polarisation and the immunological synapse. Curr Opin Cell Biol 2013;25:85–91.
2. zur Stadt U, Schmidt S, Kasper B, Beutel K, Diler AS, Henter JI, Kabisch H, Schneppenheim R, Nürnberg P, Janka G, Hennies HC. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type 4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet 2005;14:827–834.
3. Côte M, Ménager MM, Burgess A, Mahlaoui N, Picard C, Schaffner C, Al-Manjomi F, Al-Harbi M, Alangari A, Le Deist F, Gennery AR, Prince N, Cariou A, Nitschke P, Blank U, et al. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J Clin Invest 2009;119:3765–3773.
4. zur Stadt U, Rohr J, Seifert W, Koch F, Grieve S, Pagel J, Strauss J, Kasper B, Nürnberg G, Becker C, Maul-Pavicic A, Beutel K, Janka G, Griffiths G, Ehl S, et al. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood 2007;10:1906–1915.
5. Arneson LN, Brickshawana A, Segovis CM, Schoon RA, Dick CI, Leibson PJ. Cutting edge: syntaxin 11 regulates lymphocyte-mediated secretion and cytotoxicity. J Immunol 2007;179:3397–3401.
6. Halimi M, Pattu V, Marshall MR, Chang HF, Matti U, Jung M, Becherer U, Krause E, Hoth M, Schwarz EC, Retting J. Syntaxin 11 serves as a t-SNARE for the fusion of lytic granules in human cytotoxic T lymphocytes. Eur J Immunol 2014;44:573–584.
7. Spessott WA, Sanmillan ML, McCormick ME, Patel N, Villanueva J, Zhang K, Nichols CE, Giurado CG. Hemophagocytic lymphohistiocytosis caused by dominant-negative mutations in STXB2 that inhibit SNARE-mediated membrane fusion. Blood 2015;125:1566–1577.
8. Ménager MM, Menasché G, Romao M, Knappnougel P, Ho CH, Garfa M, Raposo G, Feldmann J, Fischer A, de Saint Basile G. Secretory cytotoxic granule maturation and exocytosis require the effector protein hMunc13-4. Nat Immunol 2007;8:257–267.
9. Tellam JT, McIntosh S, James DE. Molecular identification of two novel Munc-18 isoforms expressed in non-neuronal tissues. J Biol Chem 1995;270:5857–5863.
10. Hata Y, Südhof TC. A novel ubiquitous form of Munc-18 interacts with multiple syntaxins. Use of the yeast two-hybrid system to study interactions between proteins involved in membrane traffic. J Biol Chem 1995;270:13022–13028.
11. Prekner R, Klumperman J, Scheller RH. Syntaxin 11 is an atypical SNARE abundant in the immune system. Eur J Cell Biol 2000;79:771–780.
12. Scheller RH. Syntaxin 11 is an atypical SNARE abundant in the immune system. Eur J Cell Biol 2000;79:771–780.
13. Brochetta C, Suzuki R, Vita F, Soranzo MR, Claver J, Madjene LC, Attout T, Vitte J, Varin-Blank N, Zabucchi G, Rivera J, Blank U. Munc18-2 and syntaxin 3 control distinct essential steps in mast cell degranulation. J Immunol 2014;192:41–51.
14. Mandic SA, Skelin M, Johansson IU, Rupnik MS, Berggren PO, Bark C. Munc18-1 and Munc18-2 proteins modulate beta-cell Ca2+ sensitivity and kinetics of insulin exocytosis differently. J Biol Chem 2011;286:28026–28040.
15. Ungar D, Hughson FM. SNARE protein structure and function. Annu Rev Cell Dev Biol 2003;19:493–517.
21. Jahn R, Fasshauer D. Molecular machines governing exocytosis of synaptic vesicles. Nature 2012;490:201–207.
22. Marshall MR, Pattu V, Halimani M, Maier-Peuscher M, Möller ML, Becherer U, Hong W, Hoth M, Tschernig T, Bryceson YT, Rettig J. VAMP8-dependent fusion of recycling endosomes with the plasma membrane facilitates T lymphocyte cytotoxicity. J Cell Biol 2015;210:135–151.
23. Gulyas-Kovacs A, de Wit H, Milosevic I, Kochubey O, Toonen R, Klingauf J, Verhage M, Sörensen JB. Munc18-1: sequential interactions with the fusion machinery stimulate vesicle docking and priming. J Neurosci 2007;27:8676–8686.
24. Hellewell AL, Foresti O, Gover N, Porter MY, Hewitt EW. Analysis of familial hemophagocytic lymphohistiocytosis type 4 (FHL-4) mutant proteins reveals that S-acylation is required for the function of syntaxin 11 in natural killer cells. PLoS One 2014;9:e98900.
25. Hackmann Y, Graham SC, Ehl S, Höning S, Lehmberg K, Arico M, Owen DJ, Griffiths GM. Syntaxin binding mechanism and disease-causing mutations in Munc18-2. Proc Natl Acad Sci USA 2013;110:E4482–E4491.
26. Pagel J, Beutel K, Lehmberg K, Koch F, Maul-Pavicic A, Rohlf AK, Al-Jefri A, Beier R, Bomme Ousager L, Ehler K, Gross-Wieltsch U, Jorch N, Kremens B, Pekrun A, Sparber-Sauer M, et al. Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5). Blood 2012;119:6016–6024.
27. Martinez-Arca S, Proux-Gillardeaux V, Alberts P, Louvard D, Gall T. Ectopic expression of syntaxin 1 in the ER redirects TI-VAMP- and cellubrevin-containing vesicles. J Cell Sci 2003;116:2805–2816.
28. Dabrzynetskaya A, Ma J, Guerreiro-Cacais AO, Arany Z, Rudd E, Henter JI, Karre K, Levitskaya J, Levitsky V. Syntaxin 11 marks a distinct intracellular compartment recruited to the immunological synapse of NK cells to colocalize with cytotoxic granules. J Cell Mol Med 2012;16:129–141.
29. Pattu V, Qu B, Schwarz EC, Strauss B, Weins L, Bhat SS, Halimani M, Marshall M, Rettig J, Hoth M. SNARE protein expression and localization in human cytotoxic T lymphocytes. Eur J Immunol 2012;42:470–475.
30. Martin-Verdeaux S, Pombo I, Iannascoli B, Roa M, Varin-Blank N, Rivera J, Blank U. Evidence of a role for Munc18-2 and microtubules in mast cell granule exocytosis. J Cell Sci 2003;116:325–334.
31. Brochetta C, Vito F, Tiwari N, Scanduzzi L, Soranzo MR, Guerin-Marchand C, Zabucchi G, Blank U. Involvement of Munc18 isoforms in the regulation of granule exocytosis in neutrophils. Biochim Biophys Acta 2008;1783:1781–1791.
32. Bryceson YT, Pende D, Maul-Pavicic A, Gilmour KC, Ufheil H, Vraetz T, Chiang SC, Marcenaro S, Meazza R, Bondzio I, Walshe D, Janka G, Lehmberg K, Beutel K, zur Stadt U, et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 2012;119:2754–2763.
33. De Franceschi N, Hamidi H, Alanko J, Sahgal P, Ivaska J. Integrin traffic — the update. J Cell Sci 2015;128:839–852.